Pramod Terse
Overview
Explore the profile of Pramod Terse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lomash R, Dehdashti J, Shchelochkov O, Chandler R, Li L, Manoli I, et al.
Hum Gene Ther
. 2025 Feb;
36(5-6):653-662.
PMID: 39976996
Gene therapy development presents multiple challenges, and early planning is vital in the successful implementation of such programs. The Platform Vector Gene Therapy (PaVe-GT) program is a National Institutes of...
2.
Wang A, Hagen N, Padilha E, Yang M, Shah P, Chen C, et al.
Front Pharmacol
. 2022 Sep;
13:918083.
PMID: 36052127
Preclinical pharmacokinetics (PK) and ADME properties of GS-441524, a potential oral agent for the treatment of Covid-19, were studied. GS-441524 was stable in liver microsomes, cytosols, and hepatocytes of mice,...
3.
Brooks P, Ottinger E, Portero D, Lomash R, Alimardanov A, Terse P, et al.
Hum Gene Ther
. 2020 Sep;
31(19-20):1034-1042.
PMID: 32993373
No abstract available.
4.
Xu X, Wang A, Latham L, Celeste F, Ciccone C, Malicdan M, et al.
Mol Genet Metab
. 2017 Jun;
122(1-2):126-134.
PMID: 28641925
GNE myopathy is a rare, autosomal recessive, inborn error of sialic acid metabolism, caused by mutations in GNE, the gene encoding UDP-N-acetyl-glucosamine-2-epimerase/N-acetylmannosamine kinase. The disease manifests as an adult-onset myopathy...
5.
Terse P, Engelke K, Chan K, Ling Y, Sharpnack D, Saunthararajah Y, et al.
Int J Toxicol
. 2014 Mar;
33(2):75-85.
PMID: 24639139
Decitabine (5-aza-2'-deoxycytidine; DAC) in combination with tetrahydrouridine (THU) is a potential oral therapy for sickle cell disease and β-thalassemia. A study was conducted in mice to assess safety of this...
6.
Ottinger E, Kao M, Carrillo-Carrasco N, Yanjanin N, Shankar R, Janssen M, et al.
Curr Top Med Chem
. 2013 Nov;
14(3):330-9.
PMID: 24283970
In 2010, the National Institutes of Health (NIH) established the Therapeutics for Rare and Neglected Diseases (TRND) program within the National Center for Advancing Translational Sciences (NCATS), which was created...
7.
Mahfouz R, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, et al.
Clin Cancer Res
. 2013 Jan;
19(4):938-48.
PMID: 23287564
Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA-methyltransferase 1 (DNMT1). This action is S-phase dependent. Hence, genetic...
8.
Lavelle D, Vaitkus K, Ling Y, Ruiz M, Mahfouz R, Ng K, et al.
Blood
. 2011 Dec;
119(5):1240-7.
PMID: 22160381
The deoxycytidine analog decitabine (DAC) can deplete DNA methyl-transferase 1 (DNMT1) and thereby modify cellular epigenetics, gene expression, and differentiation. However, a barrier to efficacious and accessible DNMT1-targeted therapy is...